SOUTH SAN FRANCISCO, Calif.,
April 3, 2014 /PRNewswire/
-- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today
announced that the company will be presenting at the following
upcoming investor conference:
- 13th Annual Needham Healthcare
Conference
Tuesday, April 8, 2014 at the Westin
Grand Central Hotel in New York
City, NY
11:20AM – 11:50AM US ET (8:20AM – 8:50AM US
PT)
Presentations will include overviews of the company's KB001-A
development program to treat Pseudomonas aeruginosa
(Pa) infection and KB004 development program in
hematological malignancies. KB001-A is an anti-PcrV monoclonal
antibody (mAb) fragment, which KaloBios is developing for the
prevention and treatment of Pa lung infection in cystic
fibrosis (CF) patients. The company is currently conducting a 180
patient Phase 2 study of KB001-A in CF subjects with chronic
Pa lung infections. KB004 is an anti-EphA3 mAb, with
potential to treat both hematologic malignancies and solid tumors.
KaloBios is conducting a Phase 1 dose escalation study of KB004 in
hematologic malignancies seeking a maximum tolerable dose, and
commenced the Phase 2 expansion portion of the study in early
2014.
Individuals may access a live audio webcast of the Needham
presentation by visiting the event URL at:
http://ir.kalobios.com/events.cfm. A replay of the webcast
will be available on the KaloBios website for 90-days following the
live event.
About KaloBios
KaloBios Pharmaceuticals, Inc. is developing a portfolio of
proprietary, patient-targeted, first-in-class monoclonal antibodies
designed to treat severe life-threatening or debilitating diseases
for which there is an unmet medical need, with a clinical focus on
severe respiratory diseases and cancer.
Currently, KaloBios has advanced three programs to clinical
development:
- KB001-A is an anti-PcrV mAb fragment, partnered exclusively
with Sanofi Pasteur, and is being developed for the prevention and
treatment of Pa infection. KaloBios has retained rights for
the CF indication and is conducting a 180 patient Phase 2 study in
CF subjects with chronic Pa lung infection. KaloBios has
received Orphan Drug designation from both the U.S. FDA and the
European Medicines Agency for KB001-A for the treatment of
Pa lung infection in CF patients. Sanofi is pursuing a
ventilator-associated pneumonia prevention indication in the
intensive care setting, an indication which has received U.S. FDA
Fast Track Designation.
- KB004 is an anti-EphA3 mAb with potential in treating
hematologic malignancies and solid tumors. KaloBios is conducting
an ongoing Phase 1/2 study evaluating KB004 in hematologic
malignancies. The Phase 1 dose escalation portion of that study in
subjects with hematologic malignancies is ongoing. KaloBios
initiated the Phase 2 expansion portion of the study focused on
EphA3 positive patients with acute myeloid leukemia and
myelodysplastic syndrome in early 2014.
- KB003 is an anti-GM-CSF mAb with potential to treat
inflammatory diseases that was being developed for the treatment of
severe asthma. A Phase 2 clinical study in 160 patients with severe
asthma has been completed in the United
States, Europe and
Australia, which did not meet its
primary endpoint of improvement in FEV1 from baseline as
compared to placebo. KaloBios has discontinued development of this
compound in severe asthma, and is continuing to analyze the Phase 2
data to review with thought leaders and evaluate other possible
indications in order to determine next steps, if any, in the
development of KB003.
All of the company's antibodies were generated using its
proprietary Humaneered® technology, a method that
converts nonhuman antibodies (typically mouse) into recombinant
antibodies that have a high binding affinity to their target and
are designed for chronic therapeutic use. The company believes that
antibodies produced using its Humaneered® technology
offer important clinical and economic advantages over antibodies
generated by other methods in terms of high binding affinity, high
manufacturing yields, and minimal to no immunogenicity
(inappropriate immune response) upon repeat administration in
humans.
For more information on KaloBios Pharmaceuticals, please visit
our web site at http://www.kalobios.com.
Forward Looking Statements
This release
contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, and statements regarding the company's clinical
development of KB001-A, KB004 and KB003. Forward-looking statements
reflect management's current knowledge, assumptions, judgment and
expectations regarding future performance or events. Although
management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such
expectations will prove to be correct and you should be aware that
actual results could differ materially from those contained in the
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties including, but not limited
to, the potential outcomes of clinical studies of KB001-A and KB004
undertaken now or in the future; the potential, if any, for future
development of KB003; the company's limited cash reserves and its
ability to obtain additional capital on acceptable terms, or at
all, including the additional capital which will be necessary to
complete the clinical trials that the company has initiated or
plans to initiate; the company's dependence on Sanofi Pasteur for
the manufacture, development and commercialization of KB001-A; the
company's ability to successfully progress or complete further
development of its programs; the uncertainties inherent in clinical
testing; the timing, cost and uncertainty of obtaining regulatory
approvals; the company's ability to protect the company's
intellectual property; competition; changes in the regulatory
landscape or the imposition of regulations that affect the
company's products; and other factors listed under "Risk Factors"
in the company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on April
1, 2013, the quarterly reports on Form 10-Q filed on
May 14, August
19, and November 12, 2013, and
the company's other filings with the Securities and Exchange
Commission.
All forward-looking statements are expressly qualified
in their entirety by this cautionary notice. You are cautioned not
to place undue reliance on any forward-looking statements, which
speak only as of the date of this release. The company has no
obligation, and expressly disclaims any obligation to update,
revise or correct any of the forward-looking statements, whether as
a result of new information, future events or
otherwise.
For more information, visit
http://www.kalobios.com.
Contact:
Herb Cross
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3114
ir@kalobios.com
Media Contact:
Joan E. Kureczka
Kureczka/Martin Associates
Tel: (415) 821-2413
Mobile: (415)
690-0210
Joan@Kureczka-Martin.com
Logo -
http://photos.prnewswire.com/prnh/20130225/MM66380LOGO
SOURCE KaloBios Pharmaceuticals, Inc.